Provided is a method for obtaining HFO-1132(E) and/or HFO-1132(Z) efficiently. The method is a method for producing HFO-1132(E) and/or HFO-1132(Z), comprising supplying a composition containing HFO-1132(E) and/or HFO-1132(Z) to a reactor, and performing an isomerization reaction between HFO-1132(E) and HFO-1132(Z).

Disclosed is a 1,3-bisisocyanatomethylcyclohexane composition and an optical resin prepared therefrom. The composition comprises, based on the weight of 1,3-bisisocyanatomethylcyclohexane, a) 65%-95 wt % of trans-1,3-bisisocyanatomethylcyclohexane; b) greater than 0 and less than or equal to 0.5 wt %, preferably 0.02-0.5 wt % of 1,4-bisisocyanatomethylcyclohexane. Preferably, the 1,3-bisisocyanatomethylcyclohexane composition contains greater than 0 and less than or equal to 600 ppm of 1-isocyanatomethyl-3-methylcyclohexane, based on the weight of 1,3-bisisocyanatomethylcyclohexane. The 1,3-bisisocyanatomethylcyclohexane composition is used for preparing an optical resin, which can be applied to produce an optical lens with a better performance in preventing opacification and optical distortion.

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis. ##STR00001##

This invention relates to a method for preparing 1,4-cyclohexanedimethanol(CHDM), more specifically to a method for preparing 1,4-cyclohexanedimethanol having a high rate of trans isomers without an isomerization reaction step.

An object of the present invention is to provide a method for efficiently obtaining fluoroethylene

A method for producing at least one fluoroethylene compound selected from the group consisting of HFO-1132(Z/E), HFO-1132a, and HFO-1123, wherein the method comprises reacting at least one fluoroethane compound selected from the group consisting of HFC-134, HFC-134a, and HFC-125 with hydrogen (H.sub.2).

Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein Z, X, R.sup.1, R.sup.2, W, R.sup.3, R.sup.4a, R.sup.4b, L, R.sup.5a, R.sup.5b and Q are as defined in the disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases.

In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

A method for conversion of a composition containing HCFO-1233zd(Z) and HCFC-244fa to form HCFO-1233zd(E) by reacting a mixture including HCFO-1233zd(Z) and HCFC-244fa in a vapor phase in the presence of a catalyst to simultaneously isomerize HCFO-1233zd(Z) to form HCFO-1233zd(E) and dehydrohalogenate HCFC-244fa to form HCFO-1233zd(E). The catalyst may be a chromium-based catalyst such as chromium trifluoride, chromium oxyfluoride, or chromium oxide, for example.

The compound (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole, compositions and consumer products comprising the compound, methods of making the compound, and the various uses of the compound.

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I) which possess BTK inhibitory activity and are accordingly useful in therapy and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them, and to their use in the manufacture of medicaments for use in a therapeutic effect in a warm-blooded animal such as man.

##STR00001##